ArticleDiscover oncology2026
Correlating obstructive sleep apnea and lung adenocarcinoma using hub gene signatures and molecular mechanisms.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundObstructive sleep apnea (OSA) affects nearly 1 billion adults worldwide, and it is relatively common in patients with lung adenocarcinoma (LUAD). This study aimed to identify potential shared transcriptomic signatures and explore pathways linking OSA and LUAD.
methodsTranscriptomic data were obtained from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). Weighted gene co-expression network analysis (WGCNA) and protein-protein interaction (PPI) network analysis were used to identify hub genes. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to investigate the functional pathways associated with differentially expressed genes (DEGs). Univariate Cox regression and least absolute shrinkage and selection operator (LASSO)-Cox regression analyses were conducted to identify prognostic genes and construct a prognostic signature for LUAD.
resultsA total of 986 shared DEGs were identified between OSA and LUAD. Among them, 117 hub genes were selected based on the PPI network. A 12-gene signature was constructed and validated in an independent LUAD cohort. The risk score stratified LUAD patients into distinct risk groups and showed associations with estimated immune infiltration patterns. In addition, intermittent hypoxia exposure was associated with expression changes in a subset of signature genes in A549 cells.
conclusionsThis study identified shared transcriptomic features and highlighted immune-related pathways that may represent potential biological associations between OSA and LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.